About Alirocumab
            
            Class: | PCSK9 inhibitor  
Use: | Adjunct to diet and maximally tolerated statin therapy for the treatment of adults with hyperlipidemia, including heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease to reduce LDL-C levels.  
Adult dose: | 75 mg subcutaneously every 2 weeks; may be increased to 150 mg subcutaneously every 2 weeks based on LDL-C levels.  
Pediatric dose: | Safety and efficacy not established in pediatric patients under 18 years of age.  
Side eff
         
        
            
                
                
                    
                        Drug Class
                    
                    PCSK9 inhibitor
                 
                
                
                    
                        Uses & Indications
                    
                    Adjunct to diet and maximally tolerated statin therapy for the treatment of adults with hyperlipidemia, including heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease to reduce LDL-C levels.
                 
                
                
                    
                        Storage Requirements
                    
                    Store in the refrigerator (2°C to 8°C); may be kept at room temperature (up to 25°C) for up to 30 days. Do not freeze.
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: Sanofi Aventis Groupe, FRANCE
                    
                    
                    Package Size
                    2 Pre-filled Pen
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 2254.00
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        75 mg subcutaneously every 2 weeks; may be increased to 150 mg subcutaneously every 2 weeks based on LDL-C levels.
                    
                    
                        Pediatric Dose
                    
                    
                        Safety and efficacy not established in pediatric patients under 18 years of age.
                    
                 
                
                
                    
                        Side Effects
                    
                    Injection site reactions, nasopharyngitis, upper respiratory tract infections, myalgia, and diarrhea.
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Hypersensitivity to alirocumab or any component of the formulation.
         
        
        
            
                Important Warnings
            
            Risk of hypersensitivity reactions; monitor for signs of allergic reactions. Not recommended for use in patients with a history of serious hypersensitivity to alirocumab.
         
        
        
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.